Galderma Group AG agreed to acquire ZO Skin Health Inc. from Blackstone Tactical Opportunities and the Obagi family for an enterprise value of $1.5 billion. The all-cash transaction buys a California-based clinical skincare business that sells acid-based regimens through 16,500 physician and medical spa accounts. Galderma funded the acquisition with existing cash and new bank debt. The transaction allows Blackstone to exit the majority position it acquired in 2020. Galderma expects the purchase to close in the fourth quarter of 2026 or early 2027.
The acquisition shows strategic acquirers prioritising physician-dispensed product portfolios over direct-to-consumer retail brands in the dermatology sector. Private equity investors previously aggregated medical spa distribution channels, creating acquisition targets with high recurring revenues and insulated pricing power. Galderma plans to pair the ZO Skin Health portfolio with its existing Alastin and Cetaphil lines to control a larger share of the clinical skincare market. Consolidating these brands reduces distribution costs and increases negotiating leverage with independent dermatology practices and aesthetic clinics.
Under Blackstone ownership, ZO Skin Health doubled its revenue to reach $330 million in net sales for the twelve months ended June 2026. The $1.5 billion enterprise value represents a 4.5x trailing twelve-month net sales multiple. RBC Capital Markets estimated the purchase price implies a high-teens earnings before interest, taxes, depreciation and amortisation multiple. Galderma anticipates the acquisition will dilute its core EBITDA margin in 2027 due to increased commercial investment before returning to group average margins in 2028. RBC Capital Markets projected Galderma’s net leverage will increase to 1.7x following the close.
Deal terms at a glance
| Component | Detail |
|---|---|
| Buyer | Galderma Group AG |
| Target | ZO Skin Health Inc. |
| Sellers | Blackstone Tactical Opportunities and the Obagi family |
| Implied enterprise value | $1.5 billion |
| Implied equity value | Not disclosed |
| Consideration | 100% cash |
| Premium | Not applicable (private target) |
| Financing | Galderma cash reserves and bank financing |
| Conditions | Regulatory approvals and customary closing conditions |
| Expected timetable | Fourth quarter of 2026 or early 2027 |
Advisers
Galderma retained Lazard as its lead financial adviser for the transaction. J.P. Morgan provided additional financial advisory services to the buyer. Ropes & Gray LLP acted as legal counsel to Galderma. ZO Skin Health and Blackstone used Raymond James as lead financial adviser and Citigroup as financial adviser. Weil, Gotshal & Manges LLP and Paul, Weiss, Rifkind, Wharton & Garrison LLP served as legal counsel to ZO Skin Health and Blackstone.
How the deal came about
Blackstone Tactical Opportunities acquired a majority stake in ZO Skin Health in 2020 for an undisclosed sum. Dr. Zein Obagi and his family retained a minority position. Over the subsequent six years, the company expanded its product lines and distribution network to reach 16,500 accounts across 40 countries. Reuters reported that Blackstone initiated a sale process for the business in 2026, working with Citigroup and Raymond James to identify potential buyers. Galderma pursued the acquisition to add clinical dispensing capabilities to its existing dermatology operations in California. No rival bids or competing offers emerged in public filings.
Valuation and comparables
Galderma paid an enterprise value of $1.5 billion. ZO Skin Health recorded $330 million in net sales for the twelve months ended June 2026, according to the Galderma regulatory announcement. The purchase price equates to a 4.5x multiple on trailing twelve-month net sales. RBC Capital Markets calculated that the consideration implies a high-teens multiple of trailing twelve-month EBITDA. Galderma and ZO Skin Health did not disclose the target company’s exact EBITDA dollar figure. Similar historical transactions in the physician-dispensed skincare sector have commanded sales multiples between 3.5x and 5.5x, though private market deal terms remain largely undisclosed.
Financing and structure
Galderma structured the acquisition as a 100% purchase of ZO Skin Health. The buyer funded the $1.5 billion consideration using a mix of existing cash reserves and new bank financing. The companies did not disclose the precise ratio of cash to debt. Galderma stated in its corporate filing that the funding structure maintains its investment-grade credit profile. RBC Capital Markets estimated that Galderma’s pro forma net leverage will rise to approximately 1.7x in 2026. Galderma projected the transaction will be neutral to core earnings per share in the first full year after closing. The company expects a slight dilution to its core EBITDA margin in 2027 as it funds commercial expansion.
Risks, conditions and key dates
- October 2026: Galderma and Blackstone sign the definitive agreement.
- Late 2026 to early 2027: The parties anticipate clearing standard regulatory approvals and completing customary closing conditions.
- First quarter of 2027: Integration of ZO Skin Health into the Galderma portfolio begins, which Galderma expects will cause a short-term margin dilution.
- Full year 2028: Galderma forecasts the acquired business will return to broad margin parity with the parent group.
Where reports disagree
Information regarding the exact financial parameters remained consistent across major publications following the official announcement. Reuters initially reported before the definitive agreement that Galderma planned to buy ZO Skin Health for “around $1.5 billion”. Galderma later confirmed the enterprise value at exactly $1.5 billion in its regulatory filing. Financial sources agreed on the target company revenue, with Galderma stating $330 million in trailing net sales and standard wire reports confirming this figure.
Sources
Company and regulator filings
Press and analysis
- Business of Fashion, Galderma Acquire ZO Skin Health
- PE Hub, Blackstone Inks 1.5bn Sale of ZO Skin Health to Galderma
- Personal Care Insights, Galderma ZO Skin Health Acquisition
- Investing.com, Galderma to Buy ZO Skin From Blackstone for 15 Bln Reuters Reports
- Morningstar, Skincare Specialist Galderma to Buy ZO Skin Health for 15 Billion Update
- Investing.com, Exclusive Galderma Agrees to Buy ZO Skin Health for Around 15 Billion Sources Say
Facts as of 20 October 2026.
